Newsfeed
Real-time intelligence on synbio and synbio funding, regulatory milestones, deployments, and policy.
fPE7max Hits 90% Efficiency, Unlocks 3 Fungal Cancer Leads
Penn's fPE7max prime editor hits 90% efficiency in filamentous fungi, yielding 18 molecules and 3 cancer-selective leads from dormant gene clusters.
Read →Genome-Scale CRISPRi Atlas Maps iPSC Regulatory Logic
Nature Biotechnology publishes genome-scale CRISPRi atlas of human iPSCs, mapping transcriptional regulatory logic across pluripotency.
Read →fPE7max Brings Prime Editing to Filamentous Fungi
fPE7max delivers prime editing to filamentous fungi, enabling precise base substitutions, insertions, and deletions for metabolic engineering.
Read →Serapha Bio Raises $230M for AATD Base Editing Debut
Serapha Bio launches from stealth with $230M and FDA-cleared IND for a one-time base edit targeting the SERPINA1 E342K mutation.
Read →Twist Bioscience CEO Sells 18,880 Shares via 10b5-1
Twist Bioscience CEO sells 18,880 TWST shares under a pre-scheduled 10b5-1 plan on June 26, 2026.
Read →MUC16 CAR-T Cuts Bladder Tumor Growth via Catheter
MUC16-targeting CAR T cells delivered via catheter controlled bladder tumors in mice, opening a local delivery route for solid tumor CAR-T.
Read →Serapha Raises $230M Around China Gene-Editing Asset
Serapha closes $230M debut round built around a Chinese-originated gene-editing candidate, one of 2026's largest synbio therapy raises.
Read →EU Two-Tier NGT Rules Cut GMO Burden for CRISPR Crops
The EU's new two-tier NGT framework exempts qualifying CRISPR-edited crops from GMO regulation, taking effect in two years.
Read →AI Designs Caffeine-Based Molecular Switch for Cell Control
Researchers use AI to engineer caffeine as a reversible off-switch for gene circuits and CAR-T cells
Read →TRIM Platform Stacks 3+ Crop Traits via Twin Prime Editing
New genome engineering platform combines prime editing with knockouts for efficient multi-trait crop development
Read →D&D-seq Maps DNA-Protein Contacts at Single-Cell Resolution
New method uses base editor-nanobody fusions to record DNA-protein interactions in individual cells
Read →NTLA Surges 35% on Phase 3 Gene Editing Readout Anticipation
NTLA jumps 35% overnight as investors position ahead of first Phase 3 CRISPR therapy data expected this quarter
Read →Lilly Licenses Ascidian Gene Editing Tech for Kidney Disease
Eli Lilly secures exclusive licensing deal with Ascidian for gene editing platform targeting kidney diseases
Read →Lundbeck Partners with Cradle for AI Protein Design Platform
Danish pharma giant Lundbeck teams with AI protein design startup Cradle to accelerate drug discovery programs
Read →YolTech Raises $70M Series B for CRISPR Therapies in China
Chinese gene editing startup secures major funding to advance CRISPR therapeutic pipeline
Read →PRINCE System Enables Reversible Gene Editing with Small Molecules
New CRISPR system allows researchers to turn gene editing on and off with small molecules
Read →Off-Shelf Gene Editing Shows 85% Efficacy in Sickle Cell Primates
Primate study demonstrates 85% editing efficiency using allogeneic approach, potentially eliminating patient-specific manufacturing
Read →Precision BioSciences Misses Q1 Earnings Amid Gene Editing Volatility
DTIL platform company reports revenue shortfall as gene editing sector faces investor skepticism
Read →RNA Motifs Boost Prime Editing Efficiency 4x in New Study
Engineered RNA-stabilizing motifs quadruple prime editing success rates through directed evolution approach
Read →In Vivo Gene Editing Market Hits $37.75B by 2032
In vivo gene editing market projected to reach $37.75 billion by 2032, driven by CRISPR advances and clinical successes
Read →